Zeng Jian-cheng, Song Yue-ming, Liu Hao, Gong Quan, Li Tao, Liu Li-ming, Hu Yun-zhou, Pei Fu-xing, Rao Shu-cheng
Department of Orthopaedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):488-91.
To evaluate the predictive value of the Tokuhashi revised scoring system for the life expectancy of patients with spinal metastases.
A retrospective review of 447 patients with spinal metastases was performed, which comprised 291 men and 156 women with a mean age of 56. 1 years. All of the patients were scored with the Tokuhashi revised scoring system based on the available clinical, pathological and radiographic data. The relation between the survival time and the Tokuhashi revised score was analyzed.
The patients had a median survival time of 7. 9 months and a mean Tokuhashi revised score of 8. 23 points. The median survival time of 155 patients with high grade primary tumor of lung, liver, gastrointestinal tract, esophagus, bladder and pancreas was 4. 7 months. The median survival time of 146 patients with low grade primary tumor of thyroid, breast and prostate was 12 months. The median survival time of 146 patients with medium grade primary tumor of kidney, lymphoma, ovary and uterus, and unknown primary tumor was 7. 1 months. The median survival time of 211 patients with the Tokuhashi revised score of 0 to 8 points was 4 months. The median survival time of 147 patients with the Tokuhashi revised score of 9 to 11 points was 10 months. The median survival time of 89 patients with the Tokuhashi revised score of 12 to 15 points was 29 months. The differences between the groups were significant (P<0. 01 or 0. 0001). The Tokuhashi revised score was positively correlated with survival time (r=0. 833, P<0. 001).
The Tokuhashi revised score could support decision making with reliable estimation of life expectancy of patients with spinal metastases. Surgery could be a better choice to extend life span for those patients with solitary spinal metastasis of slow-growth primary tumor and those with the Tokuhashi revised score of 12 to 15 points.
评估Tokuhashi修订评分系统对脊柱转移瘤患者预期寿命的预测价值。
对447例脊柱转移瘤患者进行回顾性研究,其中男性291例,女性156例,平均年龄56.1岁。根据现有的临床、病理和影像学资料,所有患者均采用Tokuhashi修订评分系统进行评分。分析生存时间与Tokuhashi修订评分之间的关系。
患者的中位生存时间为7.9个月,Tokuhashi修订评分的平均分为8.23分。155例原发肿瘤为肺、肝、胃肠道、食管、膀胱和胰腺的高级别患者的中位生存时间为4.7个月。146例原发肿瘤为甲状腺、乳腺和前列腺的低级别患者的中位生存时间为12个月。146例原发肿瘤为肾、淋巴瘤、卵巢和子宫的中级别患者以及原发肿瘤不明的患者的中位生存时间为7.1个月。Tokuhashi修订评分为0至8分的211例患者的中位生存时间为4个月。Tokuhashi修订评分为9至11分的147例患者的中位生存时间为10个月。Tokuhashi修订评分为12至15分的89例患者的中位生存时间为29个月。组间差异具有统计学意义(P<0.01或0.0001)。Tokuhashi修订评分与生存时间呈正相关(r=0.833,P<0.001)。
Tokuhashi修订评分可为脊柱转移瘤患者预期寿命的可靠估计提供决策支持。对于原发肿瘤生长缓慢的孤立性脊柱转移瘤患者以及Tokuhashi修订评分为12至15分的患者,手术可能是延长生存期的更好选择。